Revolution Medicines, INC Form 4 insider transactions

Jeff Cislini, SVP & General Counsel of Revolution Medicines, Inc., sold 765 shares of common stock on September 25, 2026 for $207.32 per share.

Anthony Mancini, See Remarks of Revolution Medicines, Inc., sold 3,708 shares of common stock on September 24, 2026.

Elizabeth M Anderson, a Director of Revolution Medicines, Inc., sold 10,143 shares of common stock on September 22, 2026.

Anthony Mancini, See Remarks of Revolution Medicines, Inc., sold 1,764 shares of common stock on September 18, 2026 for $196.94 per share.

Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc., sold 341 shares of common stock on September 16, 2026.

Anthony Mancini, See Remarks of Revolution Medicines, Inc., sold 1,774 shares of common stock on September 16, 2026.

Stephen Michael Kelsey, See Remarks of Revolution Medicines, Inc., sold 5,569 shares of common stock on September 16, 2026.

Margaret A Horn, Chief Operating Officer of Revolution Medicines, Inc., sold 4,967 shares of common stock on September 16, 2026.

Mark A Goldsmith, See Remarks and a Director of Revolution Medicines, Inc., sold 13,988 shares of common stock on September 16, 2026.

Jeff Cislini, SVP & General Counsel of Revolution Medicines, Inc., sold 3,366 shares of common stock on September 16, 2026.

Jack Anders, Chief Financial Officer of Revolution Medicines, Inc., sold 4,053 shares of common stock on September 16, 2026.

Stephen Michael Kelsey, See Remarks of Revolution Medicines, Inc., sold 92,531 shares of common stock on September 11, 2026.

Anthony Mancini, See Remarks of Revolution Medicines, Inc., sold 15,448 shares of common stock on September 10, 2026.

Lorence H. Kim, a Director of Revolution Medicines, Inc., sold 17,090 shares of common stock on September 8, 2026.

Jeff Cislini, General Counsel of Revolution Medicines, Inc., sold 56,894 shares of common stock on August 21, 2026.

Mark A Goldsmith, See Remarks and a Director of Revolution Medicines, Inc., sold 86,000 shares of common stock on August 21, 2026.

Revolution Medicines, Inc. Director Sushil Patel reported transactions involving the acquisition of stock options and the sale of common stock under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Financial Officer, Jack Anders, reported a series of stock transactions on June 24, 2026, including the acquisition of stock options and the sale of common stock.

Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax obligations.

Mark A. Goldsmith, President and CEO of Revolution Medicines, Inc., reported a transaction involving the sale of common stock to cover tax withholding obligations.

Revolution Medicines' General Counsel, Jeff Cislini, sold 2,157 shares of common stock on June 16, 2026, to cover tax withholding obligations related to vested restricted stock units.

Revolution Medicines, Inc. reports a Form 4 filing detailing a transaction by insider Stephen Michael Kelsey.

Chief Operating Officer Margaret Horn exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc., reported transactions involving the acquisition and disposition of company stock under a pre-arranged trading plan.

Chief Global Commercialization Officer Anthony Mancini exercised options and sold 3,121 shares of Revolution Medicines stock.

Revolution Medicines, Inc. reports insider transactions by Chief Global Commercialization Officer Anthony Mancini, involving stock options and restricted stock units.

Revolution Medicines CEO Mark Goldsmith exercised 120,000 stock options and sold the resulting shares under a 10b5-1 plan.

Revolution Medicines' Chief Global Commercialization Officer, Anthony Mancini, exercised stock options and subsequently sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,073 shares of common stock for tax withholding purposes under a pre-arranged 10b5-1 plan.

Revolution Medicines' President of R&D, Stephen Michael Kelsey, sold 4,302 shares of common stock to cover tax withholding on RSU vesting.